Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a
John Manis(Broad Institute), David A. Williams(Harvard University), Erica B. Esrick(Broad Institute), Leslie Lehmann(Harvard University), Jerome Ritz(Harvard University), Neena Kapoor(Children's Hospital of Los Angeles), Kit L. Shaw(Boston Children's Hospital), Edmund K. Waller(Emory University), Myriam Armant(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Ellen Proeung(Boston Children's Hospital), Mehrdad Abedi(UC Davis Comprehensive Cancer Center), Carly Howard(Boston Children's Hospital), Akshat Jain(Loma Linda University Children's Hospital), David G. Justus(Boston Children's Hospital), Gary J. Schiller(APLA Health), Angela Treml(Medical College of Wisconsin), Mary Eapen(Medical College of Wisconsin), Heather Daley(Dana-Farber Cancer Institute), Donald B. Kohn(University of California, Los Angeles), Joseph H. Antin(Texas Oncology), Leah Cheng(Boston Children's Hospital), Colleen Dansereau(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Jeanne E. Hendrickson(Emory University), Aimee Sarnie(Boston Children's Hospital), Amy Federico(Boston Children's Hospital), Mark Walters(University of California, San Francisco), Sonali Chaudhury(Lurie Children's Hospital), Mary Horowitz(Medical College of Wisconsin), Victoria H. Coleman‐Cowger(University of Maryland, Baltimore), Helene Vincon(Boston Children's Hospital), Michael A. Pulsipher(Children's Hospital of Los Angeles)
Cited by 1
Related Papers
Gene therapy comes of age
|Science|2018|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|803
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595